Heidi Gray, MD @heidigraydrezn5 of @SeattleCCA @UWashOBGYN discusses the phase I/II study of ruxolitinib with front-line neoadjuvant and post-surgical therapy in patients with ovarian or peritoneal cancer.
_________
Read here:Â https://www.seattlecca.org/clinical-trials/gynecologic-cancer-nct02713386